Restore recycling capability of cells
Remove buildup of toxic protein
Recover patient wellbeing
Scroll to learn more
Our Science
KeifeRx is building upon its extensive clinical experience in neurodegenerative diseases to advance kinase Inhibitors that attack neurodegenerative diseases at their root cause. Our drug candidates restore autophagy and attack the three pillars of neurodegenerative diseases; microglial-mediated neuroinflammation, toxic protein build up, and vascular damage while restoring cognition. Our robust pipeline of drug candidates is designed for superior brain penetration and potency, representing a potential new generation of treatments for patients in urgent need.
KeifeRx In The News
.jpg)
JAN 9, 2026
BUSINESSWIRE
​
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson’s Disease
​
January 5, 2026
EIN Presswire
​
KeifeRx to Present at Sachs Neuroscience Forum and Biotech Showcase During J.P. Morgan Healthcare Conference Week
​
June 25, 2025
EIN Presswire
​
Journal of Clinical Medicine Publishes Results of Phase 2 Trial of Nilotinib in Treatment of Dementia with Lewy Bodies
​
June 10, 2025
EIN Presswire
​
KeifeRx Announces Expansion of Scientific Advisory Board
​